e-learning
resources
London 2016
Sunday, 04.09.2016
Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Robert Fogel (East Hanover, United States of America), Robert Fogel, Kenneth R. Chapman, Claus F. Vogelmeier, Angel FowlerTaylor, Tim Ayers, Chau Thach, Sarah Whelan, Karyn Clerkin, Francesco Patalano, Donald Banerji
Source:
International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Session:
Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Session type:
Thematic Poster
Number:
990
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Robert Fogel (East Hanover, United States of America), Robert Fogel, Kenneth R. Chapman, Claus F. Vogelmeier, Angel FowlerTaylor, Tim Ayers, Chau Thach, Sarah Whelan, Karyn Clerkin, Francesco Patalano, Donald Banerji. Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study. Eur Respir J 2016; 48: Suppl. 60, 990
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Addition of tiotropium (T) to a regular treatment with long-acting β-agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP)
Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease
Year: 2009
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept